JP2023542066A5 - - Google Patents

Info

Publication number
JP2023542066A5
JP2023542066A5 JP2022580316A JP2022580316A JP2023542066A5 JP 2023542066 A5 JP2023542066 A5 JP 2023542066A5 JP 2022580316 A JP2022580316 A JP 2022580316A JP 2022580316 A JP2022580316 A JP 2022580316A JP 2023542066 A5 JP2023542066 A5 JP 2023542066A5
Authority
JP
Japan
Prior art keywords
cancer
pharmaceutical product
product according
hydrogen
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022580316A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023542066A (ja
JP7793556B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2021/055548 external-priority patent/WO2021260579A1/en
Publication of JP2023542066A publication Critical patent/JP2023542066A/ja
Publication of JP2023542066A5 publication Critical patent/JP2023542066A5/ja
Priority to JP2025258116A priority Critical patent/JP2026048860A/ja
Application granted granted Critical
Publication of JP7793556B2 publication Critical patent/JP7793556B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022580316A 2020-06-24 2021-06-23 抗体-薬物コンジュゲートとatr阻害剤との組み合わせ Active JP7793556B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025258116A JP2026048860A (ja) 2020-06-24 2025-12-17 抗体-薬物コンジュゲートとatr阻害剤との組み合わせ

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063043498P 2020-06-24 2020-06-24
US63/043,498 2020-06-24
PCT/IB2021/055548 WO2021260579A1 (en) 2020-06-24 2021-06-23 Combination of antibody-drug conjugate and atr inhibitor

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025258116A Division JP2026048860A (ja) 2020-06-24 2025-12-17 抗体-薬物コンジュゲートとatr阻害剤との組み合わせ

Publications (3)

Publication Number Publication Date
JP2023542066A JP2023542066A (ja) 2023-10-05
JP2023542066A5 true JP2023542066A5 (cg-RX-API-DMAC7.html) 2024-06-25
JP7793556B2 JP7793556B2 (ja) 2026-01-05

Family

ID=76730926

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022580316A Active JP7793556B2 (ja) 2020-06-24 2021-06-23 抗体-薬物コンジュゲートとatr阻害剤との組み合わせ
JP2025258116A Pending JP2026048860A (ja) 2020-06-24 2025-12-17 抗体-薬物コンジュゲートとatr阻害剤との組み合わせ

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025258116A Pending JP2026048860A (ja) 2020-06-24 2025-12-17 抗体-薬物コンジュゲートとatr阻害剤との組み合わせ

Country Status (12)

Country Link
US (1) US20230330243A1 (cg-RX-API-DMAC7.html)
EP (1) EP4171650A1 (cg-RX-API-DMAC7.html)
JP (2) JP7793556B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230043109A (cg-RX-API-DMAC7.html)
CN (1) CN116635082A (cg-RX-API-DMAC7.html)
AU (1) AU2021298251A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022026205A2 (cg-RX-API-DMAC7.html)
CA (1) CA3183867C (cg-RX-API-DMAC7.html)
IL (1) IL299368A (cg-RX-API-DMAC7.html)
MX (1) MX2022016375A (cg-RX-API-DMAC7.html)
TW (1) TW202216208A (cg-RX-API-DMAC7.html)
WO (1) WO2021260579A1 (cg-RX-API-DMAC7.html)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN121038817A (zh) * 2023-04-10 2025-11-28 第一三共株式会社 抗-b7-h3抗体-药物缀合物和atr抑制剂或atm抑制剂的组合
KR20260019479A (ko) 2023-05-04 2026-02-10 레볼루션 메디슨즈, 인크. Ras 관련 질환 또는 장애를 위한 병용 요법
CN121889155A (zh) 2023-08-07 2026-04-17 锐新医药公司 用于治疗ras蛋白相关疾病或病症的rmc-6291
AU2024360465A1 (en) 2023-10-12 2026-04-09 Revolution Medicines, Inc. Macrocyclic ras inhibitors
WO2025083071A2 (en) * 2023-10-16 2025-04-24 Hummingbird Bioscience Pte. Ltd. Antibody-drug conjugates
CN122374045A (zh) * 2023-10-16 2026-07-10 蜂鸟生物科技私人有限公司 Her2结合分子
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025217307A1 (en) 2024-04-09 2025-10-16 Revolution Medicines, Inc. Methods for predicting response to a ras(on) inhibitor and combination therapies
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
US20250375445A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer
WO2026090116A2 (en) 2024-10-21 2026-04-30 Revolution Medicines, Inc. Ras inhibitors
US20260108528A1 (en) 2024-10-22 2026-04-23 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2026090245A1 (en) 2024-10-22 2026-04-30 Revolution Medicines, Inc. Use of ras inhibitors for treating cancer
WO2026106912A1 (en) 2024-11-12 2026-05-21 Revolution Medicines, Inc. Ras inhibitors
WO2026112260A1 (en) 2024-11-21 2026-05-28 Revolution Medicines, Inc. Ras inhibitors
WO2026122764A2 (en) 2024-12-06 2026-06-11 Revolution Medicines, Inc. Ras inhibitors
WO2026128688A2 (en) 2024-12-13 2026-06-18 Revolution Medicines, Inc. Ras inhibitors
WO2026161839A1 (en) 2025-01-27 2026-07-30 Revolution Medicines, Inc. Ras inhibitors

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
JP4334141B2 (ja) 1998-04-20 2009-09-30 グリカート バイオテクノロジー アクチェンゲゼルシャフト 抗体依存性細胞傷害性を改善するための抗体のグリコシル化操作
AR024464A1 (es) 1999-06-25 2002-10-02 Genentech Inc Anticuerpos anti-erbb2 humanizados.
CN103333860B (zh) 2000-10-06 2015-07-08 协和发酵麒麟株式会社 产生抗体组合物的细胞
CA2647632C (en) 2006-03-27 2017-06-27 University Of Maryland Biotechnology Institute Glycoprotein synthesis and remodeling by enzymatic transglycosylation
SA111320519B1 (ar) * 2010-06-11 2014-07-02 Astrazeneca Ab مركبات بيريميدينيل للاستخدام كمثبطات atr
JP6282232B2 (ja) 2012-02-10 2018-02-21 ユニバーシティー オブ メリーランド,ボルティモア 抗体及びそのFcフラグメントの酵素化学的糖鎖改変
US10195288B2 (en) 2012-10-11 2019-02-05 Daiichi Sankyo Company, Limited Antibody-drug conjugate
SG10201902571VA (en) 2013-12-25 2019-04-29 Daiichi Sankyo Co Ltd Anti-trop2 antibody-drug conjugate
SG11201603960XA (en) 2014-01-31 2016-07-28 Daiichi Sankyo Co Ltd Anti-her2 antibody-drug conjugate
TWI871999B (zh) 2014-04-10 2025-02-01 日商第一三共股份有限公司 抗her3抗體-藥物結合物
CA2990572C (en) 2015-06-29 2022-07-26 Daiichi Sankyo Company, Limited Method for selectively manufacturing antibody-drug conjugate
TWI926682B (zh) 2017-05-15 2026-05-21 日商第一三共股份有限公司 抗體-藥物結合物之製造方法
EP3677589B1 (en) 2017-08-31 2025-11-26 Daiichi Sankyo Company, Limited Improved method for producing antibody-drug conjugate
JP2022505041A (ja) 2018-10-15 2022-01-14 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング Dnaアルキル化剤及びatr阻害剤を使用する併用療法

Similar Documents

Publication Publication Date Title
JP2023539715A5 (cg-RX-API-DMAC7.html)
JP2023545096A5 (cg-RX-API-DMAC7.html)
JP2025041725A5 (cg-RX-API-DMAC7.html)
JPWO2020122034A5 (cg-RX-API-DMAC7.html)
JPWO2020130125A5 (cg-RX-API-DMAC7.html)
JP2023070678A5 (cg-RX-API-DMAC7.html)
FI4516357T3 (fi) Kasvaimen kasvua estävä yhdiste ja menetelmä sen valmistamiseksi ja sen käyttö
JP2018525354A5 (cg-RX-API-DMAC7.html)
JP2017186337A5 (cg-RX-API-DMAC7.html)
JP2020525542A5 (cg-RX-API-DMAC7.html)
RU2017139490A (ru) Конъюгаты лекарственных средств, содержащие антитела против клаудина 18.2
RU2018119683A (ru) Сайт-специфические конъюгаты антитела к her2 и лекарственного средства
TW202028212A (zh) Sting促效化合物
JP2010535713A5 (cg-RX-API-DMAC7.html)
JP2018537975A5 (cg-RX-API-DMAC7.html)
JP2011519941A5 (cg-RX-API-DMAC7.html)
JP2020509027A5 (cg-RX-API-DMAC7.html)
JP2008500815A5 (cg-RX-API-DMAC7.html)
JP2023542065A5 (cg-RX-API-DMAC7.html)
JP2020515578A5 (cg-RX-API-DMAC7.html)
JP2023500875A5 (cg-RX-API-DMAC7.html)
JP2024547111A5 (cg-RX-API-DMAC7.html)
JP2020500834A5 (cg-RX-API-DMAC7.html)
CN106999606A (zh) 抗体药物偶联物
JP2020534300A5 (cg-RX-API-DMAC7.html)